Back to Results

Mesa Laboratories Inc (MLAB)

Featured in High-Growth Small-Cap Stocks

Mesa Laboratories, Inc. is a Lakewood, Colorado-based company incorporated in 1982 and listed on NASDAQ under the ticker MLAB. The company develops, manufactures, sells, and services life sciences tools and quality control products used in healthcare, pharmaceutical, medical device, laboratory, and related industrial settings across North America, Europe, the Asia Pacific, and other international markets.

Its operations are organized into several segments. Sterilization and Disinfection Control provides biological, chemical, and cleaning indicators, along with testing and laboratory services, to help evaluate sterilization, disinfection, and cleaning processes. Clinical Genomics offers the MassARRAY genetic analysis system and related consumables for applications including inherited disease testing, pharmacogenetics, oncology, infectious disease, and research use. Biopharmaceutical Development supplies automated protein-analysis systems, peptide synthesis instruments, and peptide purification products. Calibration Solutions provides measurement and calibration products for environmental and process monitoring, dialysis, gas flow, air quality, and torque testing under brands such as DialyGuard, ViewPoint, DataTrace, DryCal, and BGI.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-MLAB
$117.79
-6.9% Downside
Fair
$117.50
-7.1% Downside
Fair
Great
0.5%
November 5, 2026
148.2x
3.8x
2.8x
708.1 M
840.6 M
18.5%
88.4%
2.6
73.6%
1,101.5%
Valuation • Fair Value

Mesa Laboratories Inc (NASDAQ-MLAB) Fair Value by Valuation Model

Review the available estimates for Mesa Laboratories Inc (NASDAQ-MLAB), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$117.79

Estimated downside of 6.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$115.74

Discounted cash flow valuation reference.

Ben Graham Formula Value

$9.52

Classic Ben Graham valuation formula reference.

Comps Fair Value

$119.84

Comparable-company valuation reference.

Analyst Price Target

$117.50

Analysts imply downside of 7.1%.

How to read these valuation models

Use the 6 available valuation references for Mesa Laboratories Inc (NASDAQ-MLAB) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Mesa Laboratories Inc (NASDAQ-MLAB)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

249.7 M

Current operating scale indicator.

Revenue Forecast

257 M

Forward revenue estimate.

EBITDA

45.437 M

Current operating profitability reference.

EBITDA Forecast

62 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Mesa Laboratories Inc (NASDAQ-MLAB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Mesa Laboratories Inc (NASDAQ-MLAB)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-3.06

No elevated caution signal from this screen.

Altman Z-Score

2.6

Intermediate risk zone.

FCF / Net Income

1,101.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Mesa Laboratories Inc (NASDAQ-MLAB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Mesa Laboratories Inc (NASDAQ-MLAB)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 5, 2026

Days to Earnings

48

Dividend Yield

0.5%

Current income yield reference.

Payout Ratio

73.6%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Mesa Laboratories Inc (NASDAQ-MLAB), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Mesa Laboratories Inc (NASDAQ-MLAB) Stock Forecast & Technical Outlook

Review Mesa Laboratories Inc (NASDAQ-MLAB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Mesa Laboratories Inc (NASDAQ-MLAB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Mesa Laboratories Inc (NASDAQ-MLAB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Mesa Laboratories Inc (NASDAQ-MLAB) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Mesa Laboratories Inc (NASDAQ-MLAB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Mesa Laboratories Inc (NASDAQ-MLAB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Mesa Laboratories Inc (NASDAQ-MLAB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Mesa Laboratories Inc (NASDAQ-MLAB) has a Hold consensus, with 1 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 2
Sell 0
FAQ • Fast Investor Answers

Mesa Laboratories Inc (NASDAQ-MLAB) Stock FAQ

Data-supported answers about Mesa Laboratories Inc (NASDAQ-MLAB), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$117.79
Estimated downside 6.9%
Valuation Rating
Overvalued
Estimated downside of 6.9%
Analyst Target
$117.50
Implied downside 7.1%
Financial Health
Great
Current financial-health read

The current fair value estimate for Mesa Laboratories Inc (NASDAQ-MLAB) is $117.79. This implies an estimated downside of 6.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 6.9% versus the current market price.

The available analyst price target for Mesa Laboratories Inc (NASDAQ-MLAB) is $117.50. The analyst target implies estimated downside of 7.1%.

The current financial health read for Mesa Laboratories Inc (NASDAQ-MLAB) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Mesa Laboratories Inc (NASDAQ-MLAB) is November 5, 2026.

Based on the current data, dividend yield is 0.5%.

The current P/E ratio listed for Mesa Laboratories Inc (NASDAQ-MLAB) is 148.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Mesa Laboratories Inc is 708.1 M.

The current enterprise value listed for Mesa Laboratories Inc is 840.6 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Mesa Laboratories Inc is NASDAQ-MLAB, and the stock is listed on NASDAQ.

Mesa Laboratories Inc (NASDAQ-MLAB) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Mesa Laboratories Inc is 18.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Mesa Laboratories Inc is 88.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

TMO NYSE Thermo Fisher Scientific Inc Fair Value Fair Market Cap 240.9 B
DHR NYSE Danaher Corporation Fair Value Fair Market Cap 148.9 B
A NYSE Agilent Technologies Inc Fair Value Fair Market Cap 44.113 B
IQV NYSE IQVIA Holdings Inc Fair Value Fair Market Cap 43.853 B
WAT NYSE Waters Corporation Fair Value Overvalued Market Cap 41.424 B
ILMN NASDAQ Illumina Inc Fair Value Overvalued Market Cap 36.183 B
MTD NYSE Mettler-Toledo International Inc Fair Value Fair Market Cap 27.897 B
WST NYSE West Pharmaceutical Services Inc Fair Value Fair Market Cap 25.498 B
MEDP NASDAQ Medpace Holdings Inc Fair Value Fair Market Cap 17.091 B
RVTY NYSE Revvity Inc Fair Value Fair Market Cap 16.007 B
TEM NASDAQ Tempus AI Inc Fair Value Overvalued Market Cap 14.045 B
CRL NYSE Charles River Laboratories Fair Value Fair Market Cap 13.274 B
ICLR NASDAQ ICON PLC Fair Value Fair Market Cap 12.662 B
TECH NASDAQ Bio-Techne Corp Fair Value Fair Market Cap 11.349 B
AVTR NYSE Avantor Inc Fair Value Fair Market Cap 10.497 B
BIOB NYSE Bio-Rad Laboratories B Fair Value Fair Market Cap 10.007 B
BIO NYSE Bio-Rad Laboratories Inc Fair Value Fair Market Cap 10.007 B
RGEN NASDAQ Repligen Corporation Fair Value Overvalued Market Cap 9.983 B
TXG NASDAQ 10X Genomics Inc Fair Value Overvalued Market Cap 9.979 B
BRKR NASDAQ Bruker Corporation Fair Value Fair Market Cap 9.353 B